# BEONE MEDICINES LTD. (ONC) FY2026 Q2 Balance Sheet

- Company: BEONE MEDICINES LTD. (ONC)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001628280-26-052878
- Page: https://plicit.ai/financials/onc/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/onc-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 9,175,615,000 US dollars
- **Current assets**: 7,215,805,000 US dollars
- **Non-current assets**: 1,959,810,000 US dollars
- **Liabilities**: 4,001,617,000 US dollars
- **Current liabilities**: 2,119,187,000 US dollars
- **Non-current liabilities**: 1,882,430,000 US dollars
- **Equity**: 5,173,998,000 US dollars
- **Cash and cash equivalents**: 5,098,041,000 US dollars
- **Accounts receivable, net**: 1,056,177,000 US dollars
- **Inventories, net**: 732,603,000 US dollars
- **Prepaid expenses and other current assets**: 328,984,000 US dollars
- **Property, plant and equipment, net**: 1,643,286,000 US dollars
- **Operating lease right-of-use assets**: 145,987,000 US dollars
- **Other non-current assets**: 109,581,000 US dollars
- **Intangible assets, net**: 60,956,000 US dollars
- **Accrued expenses and other payables**: 1,264,264,000 US dollars
- **Accounts payable**: 470,299,000 US dollars
- **Short-term debt**: 190,896,000 US dollars
- **Sale of future royalty liability, current portion**: 89,278,000 US dollars
- **Tax payable**: 76,315,000 US dollars
- **Operating lease liabilities, current portion**: 21,953,000 US dollars
- **Research and development cost share liability, current portion**: 6,182,000 US dollars
- **Long-term debt**: 882,163,000 US dollars
- **Sale of future royalty liability, non-current portion**: 817,035,000 US dollars
- **Other long-term liabilities**: 77,644,000 US dollars
- **Deferred tax liabilities**: 57,388,000 US dollars
- **Operating lease liabilities, non-current portion**: 48,200,000 US dollars
- **Additional paid-in capital**: 13,054,760,000 US dollars
- **Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,540,975,898 shares issued and 1,469,278,815 and 1,441,075,618 shares outstanding as of June 30, 2026 and December 31, 2025, respectively**: 147,000 US dollars
- **Accumulated deficit**: negative 7,855,539,000 US dollars
- **Accumulated other comprehensive loss**: negative 25,370,000 US dollars
- **Gross equity (calculated)**: 13,054,907,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.